ISENTRESSÂ® (raltegravir), from Merck, was as Effective as Efavirenz at Suppressing HIV Viral Load and Increasing CD4 Cell Counts in Treatment-NaÃ¯ve Patients up to 144 Weeks When Used in Combination Therapy